Not Losing Weight on a GLP-1 Drug? Plateau vs Nonresponse
A flat scale can describe several different situations: little response from the beginning, maintenance after earlier loss, or a short-term fluctuation hiding a longer trend. These situations should not lead automatically to the same decision.
Start by reconstructing what happened rather than increasing the dose yourself. A useful review considers the weight trajectory, time at the prescribed dose, interruptions, symptoms and other changes in your health or routine.
At a glance
| Review step | Bring to the appointment |
|---|---|
| Weight trajectory | Starting, recent and lowest weights |
| Treatment exposure | Dose history and time at the current dose |
| Administration | Missed doses, storage or device questions |
| Changing circumstances | Sleep, activity, symptoms and other medicines |
Maintenance and lack of response are different
Maintaining a previous reduction may still represent benefit. By contrast, minimal change throughout an adequately assessed treatment period raises a different question. Avoid diagnosing either situation from a few days of readings. If frequent weighing makes you anxious, ask the care team for a manageable way to track progress. The purpose is to inform decisions, not to create a daily pass-or-fail test.
Ask which reassessment rule applies
General US patient guidance discusses reviewing treatment when loss is below 5% after 12 weeks at the full dose. [1] That is not the same as 12 weeks from the first injection, and it is not a universal self-discontinuation rule for every product or indication. Ask your prescriber how the actual regimen, interruptions, tolerability and other health benefits affect the decision. A written review date is more useful than waiting indefinitely.
Troubleshoot without blame
Consider whether a new medicine, shift work, pain, poor sleep or digestive symptoms changed eating or activity. If you are unsure how to use the device, request another demonstration. Report missed doses honestly; they help explain treatment exposure. Do not combine injections, double doses or add supplements to break a plateau. End the review with a specific plan: what to adjust, what to monitor and when to reconsider alternatives.
Frequently asked questions
Does hunger returning prove tolerance?
No. Appetite sensations alone cannot establish the cause of a weight plateau.
Will switching drugs fix the problem?
Not necessarily. First identify what limits the current plan and discuss whether switching has a reasonable benefit-risk balance.
What if weight is stable but another health measure improves?
Bring that result to the review. It matters, but continuation still depends on the overall treatment goal, risks and applicable prescribing guidance.
Related reading
- Wegovy, Saxenda, Mounjaro and Zepbound: What’s Different?
- When Do GLP-1 Weight-Loss Drugs Start Working?
- Weight Regain After Stopping GLP-1 Medication
Korean version: 비만주사를 맞는데 살이 안 빠진다면? 무반응과 정체기를 구분하는 법
Sources
- NIDDK: Prescription medications for overweight and obesity
- Wegovy US prescribing information · June 2026
- Zepbound US prescribing information · August 2026
General health information, not an individual diagnosis or prescription. Discuss starting, changing or stopping treatment with your clinician. Seek immediate care for emergencies. Sources checked September 22, 2026; local product rules may differ.
